New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization

Viney, Kerri; Linh, Nguyễn Nhật; Gegia, Medea; Zignol, Matteo; Glaziou, Philippe; Ismail, Nazir; Kasaeva, Tereza; Mirzayev, Fuad

doi:10.1183/13993003.00361-2021

Cited by 47 publications

(46 citation statements)

References 15 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2020 the WHO introduced a new approach to managing drug-resistant tuberculosis and a new drug classification. 4 According to the WHO recommendations, bedaquiline is the first drug in an all-oral regimen to optimize treatment outcomes while minimizing the toxicity associated with injectable medicines. 6 Although some studies have been conducted on bedaquiline and delamanid to discuss their benefits and drawbacks, no systematic reviews and meta-analyses have recently been published on this topic.…”

Section: Discussionmentioning

confidence: 99%

“…Pre-XDR-TB was defined as tuberculosis caused by M. tuberculosis strains that fulfill the definition of MDR-TB/rifampin-resistant tuberculosis and that are also resistant to any fluoroquinolone, whereas XDR-TB was defined as tuberculosis caused by M. tuberculosis strains that fulfill the definition of MDR-TB/rifampin-resistant tuberculosis and are also resistant to any fluoroquinolone and at least one additional group A drug. 4 …”

Section: Methodsmentioning

confidence: 99%

“…2 However, the WHO has recently modified the definition of XDR-TB, focusing on resistance to group A drugs, which include bedaquiline. 3 , 4 The WHO has also introduced the definition of pre-XDR-TB, i.e., MDR-TB strains with additional resistance to fluoroquinolones. 4 …”

Section: Introductionmentioning

confidence: 99%

“… 3 , 4 The WHO has also introduced the definition of pre-XDR-TB, i.e., MDR-TB strains with additional resistance to fluoroquinolones. 4 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Objective: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening infectious disease. Treatment requires multiple antimicrobial agents used for extended periods of time. The present study sought to evaluate the treatment success rate of bedaquiline-based regimens in MDR-TB patients. Methods: This was a systematic review and meta-analysis of studies published up to March 15, 2021. The pooled treatment success rates and 95% CIs were assessed with the fixed-effect model or the random-effects model. Values of p < 0.05 were considered significant for publication bias. Results: A total of 2,679 articles were retrieved by database searching. Of those, 29 met the inclusion criteria. Of those, 25 were observational studies (including a total of 3,536 patients) and 4 were experimental studies (including a total of 440 patients). The pooled treatment success rate was 74.7% (95% CI, 69.8-79.0) in the observational studies and 86.1% (95% CI, 76.8-92.1; p = 0.00; I2 = 75%) in the experimental studies. There was no evidence of publication bias (p > 0.05). Conclusions: In patients with MDR-TB receiving bedaquiline, culture conversion and treatment success rates are high even in cases of extensive resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“… 3 , 4 The WHO has also introduced the definition of pre-XDR-TB, i.e., MDR-TB strains with additional resistance to fluoroquinolones. 4 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recently, the World Health Organization (WHO) has released a revised definition of extensively drug-resistant tuberculosis (XDR-TB) that should be used for clinical and surveillance purposes starting from January 1 st , 2021 [1,2]. The previous definition of XDR-TB TB was TB that is resistant to any fluoroquinolone (levofloxacin and/or moxifloxacin) and to at least one of three second-line injectable drugs (SLI, capreomycin, kanamycin and amikacin), in addition to multidrug resistance.…”

mentioning

confidence: 99%

Impact of the revised definition of extensively drug-resistant tuberculosis

et al. 2021

View full text Add to dashboard Cite

According to French regulation at the time of start of the study and in accordance with the ethical standards of our hospitals' institutional review boards (Committee for the Protection of Human Subjects), informed consent was not sought because this observational study did not modify existing diagnostic or therapeutic strategies, and is focused on strains' drug susceptibility without collection of patients' data.

show abstract

Nitrothiazole‐Thiazolidinone Hybrids: Synthesis and in Vitro Antimicrobial Evaluation

Hart

Legoabe

Jesumoroti

et al. 2022

Chemistry & Biodiversity

View full text Add to dashboard Cite

Herein we report the synthesis of novel compounds inspired by the antimicrobial activities of nitroazole and thiazolidin-4-one based compounds reported in the literature. Target compounds were investigated in vitro for antitubercular, antibacterial, antifungal, and overt cell toxicity properties. All compounds exhibited potent antitubercular activity. Most compounds exhibited low micromolar activity against S. aureus and C. albicans with no overt cell toxicity against HEK-293 cells nor haemolysis against human red blood cells. Notably, compound 3b exhibited low to sub-micromolar activities against Mtb, MRSA, and C. albicans. 3b showed superior activity (0.25 μg/ml) against MRSA compared to vancomycin (1 μg/ml).

show abstract

New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization

Abstract: The definition of extensively drug resistant tuberculosis has been updated by the World Health Organization and pre-extensively drug-resistant tuberculosis has been defined https://bit.ly/30Fdffc

Cited by 47 publications

References 15 publications

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis

Impact of the revised definition of extensively drug-resistant tuberculosis

Nitrothiazole‐Thiazolidinone Hybrids: Synthesis and in Vitro Antimicrobial Evaluation

Contact Info

Product

Resources

About